NEW DELHI (AP) — India recorded its biggest single-day spike in coronavirus cases on Monday as the government eased one of the world's strictest lockdowns to allow some manufacturing and agricultural activity to resume.

An additional 1,553 cases were reported over 24 hours, raising the national total past 17,000. At least 543 people have died from COVID-19, the respiratory disease caused by the virus, and epidemiologists forecast the peak may not be reached before June.

The shelter-in-place orders imposed in India on March 24 halted all but essential services. Starting Monday, limited industry and farming were allowed to resume where employers could meet social distancing and hygiene norms, and migrant workers can travel within states to factories, farms and other work sites.

“In the event a group of migrants wish to return to their places of work within the state where they are presently located, they would be screened and those who are asymptomatic would be transported to their respective places of work,” India’s home ministry said in a letter to state governments.

However, government surveys in the central Indian state of Maharashtra, the worst-hit by the virus, have suggested few companies eligible to restart operations can do so because they are required to transport and shelter workers as a virus-prevention measure.

The loosening of restrictions comes as India continues to ramp up testing, build up stocks of ventilators and personal protective equipment and prepare makeshift isolation wards and dedicated COVID-19 hospitals.

In Mumbai, the capital of Maharashtra and home to Asia's largest slum, city authorities were planning to administer hydroxycloroquine to thousands of slum-dwellers over 14 days to gauge whether the drug helped to slow the spread of the disease in a place where social distancing norms aren't possible to achieve. It was unclear how many people would participate in the experiment, or when it would begin. President Donald Trump has touted the malaria drug to treat COVID-19, though its efficacy against the disease is unproven.